Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Apr;7(4):336-47.
doi: 10.1593/neo.04532.

A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040

Affiliations

A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040

Yuli Wang et al. Neoplasia. 2005 Apr.

Abstract

PD184352/CI-1040 is a potent and selective MEK1/2 inhibitor that represents the first MEK-targeted agent to enter clinical trials. Here, we report the development and molecular characterization of CI-1040 resistance in the murine colon 26 (C26) carcinoma cell line. The growth rate of the resistant line (C26/CI-1040r) in the presence of 2 microM CI-1040 is comparable to that of parental C26 cells in the absence of CI-1040. C26/CI-1040r cells are approximately 100-fold more resistant than the parental line to CI-1040 inhibition in soft agar and are less sensitive to the induction of apoptosis that normally occurs in response to CI-1040 treatment. K-ras expression is significantly elevated in C26/CI-1040r cells. We confirmed a causative role for K-ras in conferring resistance to CI-1040 by transfecting K-ras into parental C26 cells, whereupon an elevation in the levels of phosphorylated ERK1/2 was observed in addition to resistance to CI-1040. Furthermore, an in vivo-derived MEK inhibitor-resistant line also shows increased K-ras expression. Our data suggest that increasing activated K-ras expression represents one potential mechanism by which tumor cells that initially are responsive to blockade of the MAP kinase pathway can overcome their sensitivity to MEK inhibition.

PubMed Disclaimer

Figures

Figure 1
Figure 1
C26/CI-1040r cells are resistant to the growth-inhibitory effects of CI-1040. (A) Dose response of CI-1040 in C26/CI-1040r and its parental cell line C26 in a soft agar growth assay. (B) Cell morphology and cell density of C26 and C26/CI-1040r in cell culture. Cells were seeded in six-well plates at 50,000 cells/well. One day after cell plating, the cells were treated with DMSO or 2 µM CI-1040 for 2 days. (C) Effect of CI-1040 on cell monolayer growth. After pictures were taken as shown in (B), both floating and attached cells were combined and then counted with a Coulter Counter. (D–F) Effect of CI-1040 on C26 parental cell growth was measured by [14C]thymidine incorporation.
Figure 1
Figure 1
C26/CI-1040r cells are resistant to the growth-inhibitory effects of CI-1040. (A) Dose response of CI-1040 in C26/CI-1040r and its parental cell line C26 in a soft agar growth assay. (B) Cell morphology and cell density of C26 and C26/CI-1040r in cell culture. Cells were seeded in six-well plates at 50,000 cells/well. One day after cell plating, the cells were treated with DMSO or 2 µM CI-1040 for 2 days. (C) Effect of CI-1040 on cell monolayer growth. After pictures were taken as shown in (B), both floating and attached cells were combined and then counted with a Coulter Counter. (D–F) Effect of CI-1040 on C26 parental cell growth was measured by [14C]thymidine incorporation.
Figure 1
Figure 1
C26/CI-1040r cells are resistant to the growth-inhibitory effects of CI-1040. (A) Dose response of CI-1040 in C26/CI-1040r and its parental cell line C26 in a soft agar growth assay. (B) Cell morphology and cell density of C26 and C26/CI-1040r in cell culture. Cells were seeded in six-well plates at 50,000 cells/well. One day after cell plating, the cells were treated with DMSO or 2 µM CI-1040 for 2 days. (C) Effect of CI-1040 on cell monolayer growth. After pictures were taken as shown in (B), both floating and attached cells were combined and then counted with a Coulter Counter. (D–F) Effect of CI-1040 on C26 parental cell growth was measured by [14C]thymidine incorporation.
Figure 2
Figure 2
The C26/CI-1040r cell line is less sensitive to CI-1040-induced apoptosis. Cells were plated on regular or polyHEMA-coated 96-well tissue culture plates. One day after cell plating, the cells were treated with the indicated concentration of CI-1040. The cells were then harvested for the apoptosis assay 24 hours after compound treatment. (A) Apoptosis assay for C26 and C26/CI-1040r cells grown on regular tissue culture plates. (B) Apoptosis assay for C26 and C26/CI-1040r cells grown on polyHEMA-coated 96-well plates.
Figure 3
Figure 3
C26/CI-1040r is less sensitive to CI-1040-induced cell cycle arrest than the parental C26 cell line. Cells were treated for 24 hours with CI-1040 and then cell cycle analysis was run on the BD LSR flow cytometer. A total of 25,000 events was collected per analysis.
Figure 4
Figure 4
The basal level of ERK1/2 phosphorylation increases in C26/CI-1040r cells, but the sensitivity of MEK1/2 to CI-1040 inhibition is not significantly altered. (A) Effect of CI-1040 on ERK phosphorylation in C26 and C26/CI-1040r cells. Cells were treated with the indicated concentration of CI-1040 for 1 hour and then harvested for Western analysis. Two different exposures of the same immunoblots are shown. (B) Effect of CI-1040 on MEK1 and MEK2 in C26 and C26/CI-1040r cells. MEK1 or MEK2 from C26 or C26/CI-1040r cells was immunoprecipitated with the corresponding antibody. The kinase activities were assayed with GST-ERK1K71R as substrate as described in the Materials and Methods section. The exposure time was adjusted to give a similar basal level of intensity (without compound treatment). (C) Effect of CI-1040 treatment on ERK and MEK phosphorylation. C26 (P) and C26/CI-1040r (R) cells were treated with DMSO (-) or 2 µM CI-1040 (+) as described in the Materials and Methods section.
Figure 5
Figure 5
K-ras is activated and overexpressed in CI-1040-resistant cells. (A) K-ras mRNA is upregulated in C26/CI-1040r cells. K-ras signal data are derived from genechip experiments (Table 1). (B and D) K-ras protein is overexpressed in both in vitro- and in vivo-derived resistant cells. The K-ras from C26 parental or resistant cells was immunoprecipitated with a pan-ras antibody (SC-35AC) and blotted with K-ras antibody (SC-30). (C) K-ras is activated. The Ras activation assay was performed with parental and C26/CI-1040r cell lysate using Upstate's ras activation assay kit.
Figure 6
Figure 6
Overexpression of K-ras in C26 cells confers CI-1040 resistance. CI29-2, CI29-13, and CI29-16 are single clones from C26 parental cells transfected with K-rasV12 selected in the presence of 2 µM CI-1040. 33-10, 33-11, and 33-4 are single clones from C26 parental cells transfected with K-rasV12 selected in the absence of CI-1040. (A) Soft agar assay. (B) Overexpression of K-ras increased ERK1/2 phosphorylation.

Similar articles

Cited by

References

    1. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst. 2001;93:1062–1074. - PubMed
    1. Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989;49:4682–4689. - PubMed
    1. Vojtek AB, Der CJ. Increasing complexity of the Ras signaling pathway. J Biol Chem. 1998;273:19925–19928. - PubMed
    1. Chong H, Vikis HG, Guan KL. Mechanisms of regulating the Raf kinase family. Cell Signal. 2003;15:463–469. - PubMed
    1. Cobb MH, Xu S, Hepler JE, Hutchison M, Frost J, Robbins DJ. Regulation of the MAP kinase cascade. Cell Mol Biol Res. 1994;40:253–256. - PubMed

MeSH terms

LinkOut - more resources